|
|
|
|
|
|
Sponsored by: |
Institut Gustave Roussy |
Information provided by: | Institut Gustave Roussy |
ClinicalTrials.gov Identifier: | NCT00407433 |
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
Condition | Intervention | Phase |
Medulloblastoma Central Nervous System Tumors Neuroblastoma Osteosarcoma |
Drug: Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®) |
Phase II |
MedlinePlus related topics: | Cancer Neuroblastoma |
ChemIDplus related topics: | Gemcitabine hydrochloride Gemcitabine Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 2 Single-Arm Studies of Gemcitabine in Combination With Oxaliplatin Refractory and Relapsed Pediatric Solid Tumors |
Estimated Enrollment: | 156 |
Ages Eligible for Study: | 6 Months to 20 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adequate organ function:
Exclusion Criteria:
Contact: Birgit Geoerger, MD | 00 331 42 11 46 61 | geoerger@igr.fr |
Contact: Marie Cécile Le Deley, MD | 00 331 42 11 54 44 | ledeley@igr.fr |
France | |||||
Institut Gustave Roussy | Recruiting | ||||
Villejuif, France, 94800 | |||||
Contact: Birgit Geoerger, MD 00 331 42 11 46 61 geoerger@igr.fr | |||||
Contact: Marie Cécile Le Deley, MD 00 331 42 11 54 44 ledeley@igr.fr |
Institut Gustave Roussy |
Principal Investigator: | Birgit Geoerger, MD | Institut Gustave Roussy |
Study ID Numbers: | IGR 1205, ITCC-004-GEMOX |
First Received: | December 4, 2006 |
Last Updated: | July 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00407433 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|